Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AstraZeneca

GlaxoSmithKline

Novartis

Vaxart

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.

Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants

Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth

FDA a pproves Dupixent ® (dupilumab) as f irst b iologic m edicine for c hildren a ged 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

2,500 Sanofi Massachusetts-based employees come together in a shared space to improve collaboration while growing our science-centered, patient-focused culture Single integrated campus supports Play to Win strategy to focus on growth, lead with innovation, accelerate efficiencies, and reinvent the way we work CAMBRIDGE, Mass. , June 7, 2022 /PRNewswire/ -- Sanofi announces the opening of the company's new campus at Cambridge Crossing in Cambridge, Massachusetts.

Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing

Sanofi launches 2022 global E mployee S tock P urchase P lan for 86.000 people

Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people

The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.

Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug

Regeneron Pharmaceuticals

Regeneron will gain exclusive worldwide development, commercialization, and manufacturing rights to the drug Libtayo.

Regeneron Will Buy Cancer Drug Rights From Sanofi for Up to $1.1 Billion

Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo.

Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration

Sanofi grant s Regeneron worldwide exclusive license rights to Libtayo ® ( cemiplimab )

Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)

Sanofi SNY, -3.45% SAN, +1.17% said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitrum AB SOBI, +5.00% . The company said it plans to ask the FDA to approve efanesoctocog alfa this summer.

FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designation

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) for the lead drug candidate Dupixent (dupilumab) for the treatment of patients with prurigo.

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.

Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag

The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.

Sanofi Ordered to Delay Trial for OTC Cialis. The Stock Falls.

STERIS

Market downturns don't affect stocks equally.

3 Unstoppable Stocks That Are Higher Than Before the Market Correction

Sanofi's strong reliance on a single product Dupixent poses risks as competition in atopic dermatitis segment increases. It struggled to show any superiority in COVID-19 vaccine development and is still catching up with mRNA technology.

Sanofi: Reliance On One Drug Strategy May Bite

Alkermes

Sesen Bio Inc.

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

There's a lot to like about this big pharma juggernaut.

This Safe Stock Is Dirt Cheap -- and It's Beating the Market

BAE Systems PLC

Legal & General Group PLC

Unilever

U.S. equity markets aren't the only place where you can find income-producing royalty. Indeed, a quick look across the pond yields dozens, in the form of the European Dividend Aristocrats.

European Dividend Aristocrats: 40 Top International Dividend Stocks

A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects.

Sanofi ordered to compensate French family for epilepsy drug side effects

Pfizer

These three pharma stocks each pay market-beating dividends to shareholders.

3 Top Biotech Stocks to Buy Right Now

Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.

EuroAPI gains on market debut after spin-off from Sanofi

Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.

Press Release: Foundation S: Sanofi's new philanthropic spearhead

Sanofi SA (NASDAQ:SNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Research & Development William Sibold - EVP, Specialty Care & President, Sanofi North America Thomas Triomphe - Head, Vaccines Olivier Charmeil - Head, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP & CFO Brendan O'Callaghan - EVP, Global Industrial Affairs Conference Call Participants Laura Sutcliffe - UBS Investment Bank Graham Parry - Bank of America Merrill Lynch Wimal Kapadia - Sanford C. Bernstein & Co. Luisa Hector - Berenberg Richard Vosser - JPMorgan Chase & Co. Timothy Anderson - Wolfe Research Peter Welford - Jefferies Keyur Parekh - Goldman Sachs Group Florent Cespedes - Societe Generale Mark Purcell - Morgan Stanley Peter Verdult - Citigroup Eva Schaefer-Jansen Good morning, good afternoon and good evening to everyone.

News for Sanofi Stock (SNY)